ImmunityBio Hits 52-Week High, Shares Jump 41.9% After EU Clears Anktiva
ImmunityBio shares climbed to a 52-week high, hitting $8.68 intraday and closing up 41.86% at $8.54, on news of aggressive Anktiva expansion. The European Commission granted conditional marketing authorization for Anktiva + BCG, paving the way for sales across 33 EU countries.
1. Share Price Climbs to New 52-Week High
ImmunityBio shares surged to a new 52-week high, reaching $8.68 intraday and closing at $8.54, up 41.86% on elevated trading volume as investors reacted to regulatory progress for Anktiva.
2. EU Grants Conditional Marketing Authorization
The European Commission issued a conditional marketing authorization for Anktiva + BCG in BCG-unresponsive non-muscle invasive bladder cancer, following a positive opinion from the European Medicines Agency, designed to accelerate access.
3. Expansion into 33 European Markets
Upon full approval, ImmunityBio will be able to market Anktiva across 33 EU countries, joining existing authorizations in the US, UK and Saudi Arabia; over 80% of treated patients have preserved their bladder through three years of follow-up.